Citi Maintains Medtronic(MDT.US) With Hold Rating, Announces Target Price $92

花旗維持美敦力(MDT.US)持有評級，目標價92美元

moomoo資訊 · 10/01 06:31 · 評級/大行評級

Citi analyst Joanne Wuensch maintains $Medtronic (MDT.US)$ with a hold rating, and sets the target price at $92.

According to TipRanks data, the analyst has a success rate of 64.0% and a total average return of 6.4% over the past year.

AnalystRecentRatingAutoNews_201438_20241001_0fa7dd684e0b6f105a29643696177d66883859ec_1727872220849401_mm_en

Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:

The firm questions whether the recent upswing in medical technology stocks is sustainable as the industry approaches the third-quarter financial reports. Adopting a cautious stance, analysts note that the third quarter typically presents challenges within the medical technology sector, with particular focus on the 2025 outlook and discussions regarding projections for the upcoming year potentially influencing stock movement in the short term.
Utilization in MedTech continues to show positive trends going into the third quarter, and the outlook for capital expenditures into the following year remains robust. In the segment of life science tools, expectations are set for bioprocess trends to improve in the latter half of the year. However, discussions persist regarding the future of instrument demand and the impact of potential stimulus measures in China, particularly considering the recent performance of stocks in this sector. Medtronic, among other selected companies, is identified for potential outperformance, with a positive outlook sustained for Exact Sciences as the third-quarter financial results approach.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

花旗分析師Joanne Wuensch維持$美敦力 (MDT.US)$持有評級，目標價92美元。

根據TipRanks數據顯示，該分析師近一年總勝率為64.0%，總平均回報率為6.4%。

AnalystRecentRatingAutoNews_201438_20241001_0fa7dd684e0b6f105a29643696177d66883859ec_1727872220849401_mm_tc

此外，綜合報道，$美敦力 (MDT.US)$近期主要分析師觀點如下：

該公司質疑，隨着該行業接近第三季度財務報告，近期醫療科技股的上漲是否可持續。分析師採取謹慎的立場指出，第三季度通常會給醫療技術行業帶來挑戰，特別關注2025年的展望，以及關於來年預測的討論，可能會在短期內影響股票走勢。
進入第三季度，醫療科技的利用率繼續顯示出積極的趨勢，下一年的資本支出前景仍然強勁。在生命科學工具領域，預計下半年生物工藝趨勢將有所改善。但是，關於未來工具需求和中國潛在刺激措施影響的討論仍在繼續，特別是考慮到該行業股票的近期表現。美敦力和其他入選公司被認爲有可能跑贏大盤，隨着第三季度財務業績的臨近，Exact Sciences的前景保持樂觀。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Citi Maintains Medtronic(MDT.US) With Hold Rating, Announces Target Price $92

Citi Maintains Medtronic(MDT.US) With Hold Rating, Announces Target Price $92

風險及免責聲明

聲明